Nurix Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Year	Current	2023	2022	2021	2020
Market Capitalization	723	302	584	1,286	1,656
Market Cap Growth	-	-48.35%	-54.57%	-22.36%	-
Enterprise Value	509	43	286	1,003	1,375
PE Ratio	-4.17	-2.10	-3.24	-10.97	-38.30
PS Ratio	8.95	3.92	15.12	43.22	92.93
PB Ratio	4.29	1.51	1.92	3.76	5.71
P/FCF Ratio	-7.20	-3.36	-3.40	-14.28	-357.44
P/OCF Ratio	-8.07	-3.71	-3.66	-15.24	-20700.24
EV/Sales Ratio	6.29	0.57	7.41	33.71	77.14
EV/EBITDA Ratio	-2.98	-0.33	-1.69	-9.04	-22.32
EV/EBIT Ratio	-2.68	-0.30	-1.59	-8.57	-21.55
EV/FCF Ratio	-4.63	-0.48	-1.66	-11.14	-296.72
Debt / Equity Ratio	0.17	0.15	0.04	0.04	-
Debt / EBITDA Ratio	-0.22	-0.23	-0.07	-0.12	-
Debt / FCF Ratio	-0.35	-0.34	-0.07	-0.14	-
Quick Ratio	2.79	3.32	4.39	4.56	6.32
Current Ratio	2.86	3.40	4.51	4.70	6.70
Asset Turnover	0.24	0.22	0.09	0.06	0.08
Return on Equity (ROE)	-67.10%	-59.50%	-59.20%	-33.80%	-37.20%
Return on Assets (ROA)	-43.60%	-41.60%	-42.20%	-24.90%	-19.60%
Return on Capital (ROIC)	-79.50%	-67.10%	-58.25%	-33.18%	-22.39%
Earnings Yield	-19.98%	-47.71%	-30.88%	-9.11%	-2.61%
FCF Yield	-11.58%	-29.75%	-29.45%	-7.00%	-0.28%
Buyback Yield / Dilution	-1.62%	-11.79%	-13.32%	-173.68%	-376.03%
Total Shareholder Return	-1.62%	-11.79%	-13.32%	-173.68%	-376.03%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).